The clinicopathological features of HCC cases with or without po-TACE treatment
| Variable | Controls (n = 160) | Po-TACEs (n = 158) | χ2 | P | ||
|---|---|---|---|---|---|---|
| n | % | n | % | |||
| Age (years old)a | ||||||
| 48 | 91 | 56.9 | 88 | 55.7 | 0.045 | 0.832 |
| > 48 | 69 | 43.1 | 70 | 44.3 | ||
| Gender | ||||||
| Male | 113 | 70.6 | 102 | 64.6 | 1.337 | 0.248 |
| Female | 47 | 29.4 | 56 | 35.4 | ||
| Race | ||||||
| Han | 93 | 58.1 | 79 | 50.0 | 2.113 | 0.146 |
| Zhuang | 67 | 41.9 | 79 | 50.0 | ||
| HBV status | ||||||
| Negative | 47 | 29.4 | 54 | 34.2 | 0.846 | 0.358 |
| Positive | 113 | 70.6 | 104 | 65.8 | ||
| HCV status | ||||||
| Negative | 146 | 91.3 | 137 | 86.7 | 1.674 | 0.196 |
| Positive | 14 | 8.8 | 21 | 13.3 | ||
| Smoking status | ||||||
| No | 121 | 75.6 | 121 | 76.6 | 0.040 | 0.841 |
| Yes | 39 | 24.4 | 37 | 23.4 | ||
| Drinking status | ||||||
| No | 113 | 70.6 | 122 | 77.2 | 1.790 | 0.181 |
| Yes | 47 | 29.4 | 36 | 22.8 | ||
| AFP (ng/L) | ||||||
| 20 | 57 | 35.6 | 59 | 37.3 | 0.101 | 0.750 |
| > 20 | 103 | 64.4 | 99 | 62.7 | ||
| Liver cirrhosis | ||||||
| No | 37 | 23.1 | 40 | 25.3 | 0.208 | 0.648 |
| Yes | 123 | 76.9 | 118 | 74.7 | ||
| ES gradeb | ||||||
| Low | 80 | 50.0 | 88 | 55.7 | 1.036 | 0.309 |
| High | 80 | 50.0 | 70 | 44.3 | ||
| MVD | ||||||
| No | 55 | 34.4 | 56 | 35.4 | 0.040 | 0.842 |
| Yes | 105 | 65.6 | 102 | 64.6 | ||
a Age is grouped according to the average age of patients with HCC (47.94 years old 9.98 years old); b ES grade is divided into two groups: low grade (ES-I and -II grade) and high grade (ES-III and -IV grade). AFP: α-fetoprotein
We thank Dr. Qiu-Xiang Liang, Dr. Yun Yi, Yun Xia, Yong-Zhi Huang, and Dr. Yuan-Feng Zhou for sample collection and management, Dr. Hua Huang for molecular biochemical technique.
LYH and QQL: Methodology, Formal analysis, Data curation, Writing—review & editing. QYS: Investigation, Resource, Writing—review & editing. XYZ: Investigation, Formal analysis, Writing—review & editing. XDL: Conceptualization, Funding acquisition, Supervision, Project administration, Writing—original draft, Writing—review & editing. All authors read and approved the submitted version.
The authors declare that they have no conflicts of interest.
The collection of removed tumor samples and clinicopathological information are approved by the Ethics Committee of Youjiang Medical University for Nationalities, China (No. AYJM20150118) and comply with the Declaration of Helsinki.
Informed consent to participate in the study was obtained from all participants.
Not applicable.
Not applicable.
This study was supported in part by Guangxi Training Program for Medical High-level Academic Leaders [Guiweikejiaofa (2020)-15], Bose Talent Highland [2020-3-2], Building Projects from the Key Laboratory of Molecular Pathology (Hepatobiliary Diseases) of Guangxi [Guiweikejiaofa (2020)-17] and the Key Laboratory of Tumor Molecular Pathology of Guangxi Colleges & Universities [Guijiaokeyan (2022)-10], and Clinical Key Specialty Building Project (For Pathology) of Guangxi [Guiweiyifa (2022)-21]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
© The Author(s) 2023.